.RESEARCH STUDY HIGHLIGHT.16 October 2024.
In the NIAGARA trial, the addition of perioperative durvalumab to regular procedure for muscle-invasive sac cancer improved event-free and also overall survival, noting a brand new therapy possibility for this ailment.